Therapeutic Vaccines Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast till 2031

The therapeutic vaccines market size is projected to reach US$ 2,934.57 million by 2031 from US$ 1,244.94 million in 2024. The market is expected to register a CAGR of 13.0% during 2024–2031. Advancements in vaccine technology are likely to remain key trends in the therapeutic vaccines market.

Therapeutic Vaccines Market Analysis

The therapeutic vaccines market is expected to witness substantial growth in the coming years due to advancements in immunotherapy and the increasing prevalence of chronic diseases, such as cancer and infectious diseases. These vaccines are administered to treat diseases by stimulating the immune system to target and destroy diseased cells. The therapeutic vaccines market is poised for significant growth with a surging focus on personalized medicine and technological innovations. Factors such as government investments, rising healthcare demands, and novel vaccine platform development further contribute to its expansion. The market is expected to experience strong growth due to increasing healthcare investments, advancements in vaccine technologies, and a growing demand for targeted therapeutic solutions.

Therapeutic Vaccines Market Overview

The therapeutic vaccines market is rapidly evolving, fueled by advancements in immunotherapy and growing awareness of vaccine-based treatment approaches. The market is particularly driven by innovations in cancer immunotherapy, which involves developing therapeutics to enhance the immune system's ability to recognize and destroy tumor cells. The increasing prevalence of chronic diseases and the growing awareness of personalized medicine further stimulate the demand for therapeutic vaccines. The German Cancer Research Center (DKFZ) conducts pioneering research in cancer immunotherapy and vaccine development, contributing to the country's role as a hub for medical innovation. In August 2024, researchers at the DKFZ introduced a novel vaccine aimed at boosting HPV vaccination rates, targeting cancer-causing human papillomaviruses (HPV). This innovative vaccine is cost-effective and has shown efficacy in protecting mice from nearly all types of cancer-causing HPV. The vaccine also stimulates cellular immune responses against HPV-infected cells and has a therapeutic effect against existing infections. The ultimate objective of researchers is to develop a therapeutic vaccine for individuals who have already contracted HPV, particularly those who may have developed HPV-related cancer or precancerous lesions. Thus, a strong research ecosystem and collaborative efforts between academic institutions, hospitals, and biotech companies are accelerating the development of new therapeutic vaccines in Germany.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Therapeutic Vaccines Market: Strategic Insights

Therapeutic Vaccines Market

• Market Size 2024
  US$ 1,244.94 Million
• Market Size 2031
  US$ 2,934.57 Million

Market Dynamics

GROWTH DRIVERS

• Rising Prevalence of Chronic Conditions

FUTURE TRENDS

• Increasing Investments and Funding for Vaccine Development

OPPORTUNITIES

• Extending Product Pipeline

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product

• Cancer Vaccines
• Infectious Disease Vaccines

Technology

• Allogenic Vaccines
• Autologous Vaccines

End User

• Hospitals
• Clinics

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Therapeutic Vaccines Market Drivers and Opportunities

Rising Prevalence of Chronic Conditions Bolsters Market Growth

Chronic conditions such as cancer, neurological diseases, and autoimmune diseases are becoming more widespread globally due to factors such as aging, lifestyle changes, and environmental influence. According to the World Health Organization's (WHO) Noncommunicable Diseases Factsheet 2023, these diseases account for 41 million global deaths annually, equivalent to 74% of total mortality. Per the Global Cancer Facts & Figures, ~20 million cancer cases were diagnosed in 2022, and 9.7 million people succumbed to the disease in the same year. Moreover, as per an article titled "The Global Landscape of Autoimmune Disease," published in February 2024, autoimmune diseases affect 5–10% of the industrial world population; it also states that ~50 million Americans are affected by autoimmune diseases. In addition, as per the WHO multiple sclerosis factsheet, over 1.8 million people in the world suffered from multiple sclerosis as of August 2023.

Thus, the surging incidences of various chronic conditions highlight the urgent need for innovative therapeutic interventions. Therapeutic vaccines are designed to treat existing diseases instead of preventing their onset. These vaccines stimulate the body's immune system to target and treat specific diseases. In cancer treatment, the Sipuleucel-T (Provenge) vaccine has demonstrated the potential to improve survival rates in prostate cancer patients. Amid the demand for innovative treatments for chronic diseases, therapeutic vaccines are expected to offer a new approach to long-term disease management and improve patient outcomes globally. Thus, the rising prevalence of chronic diseases fuels the therapeutic vaccines market growth.

Extending Product Pipeline to Create Growth Opportunities

As the global demand for innovative treatment options rises, the therapeutic vaccines sector has witnessed robust investments and advancements in vaccine development, driven largely by the rising number of clinical candidates progressing through various stages of development. R&D efforts in biotechnology yield cutting-edge therapeutic vaccines that target various diseases, particularly newer infections and chronic ones such as cancer. Moderna's mRNA-4157 is currently in phase 2 trials, with early-stage results showing promising potential in combination with checkpoint inhibitors for melanoma treatment. In addition to oncology, the therapeutic vaccine pipeline is also growing in areas such as autoimmune diseases and infectious diseases (HIV, HPV, and HBV infections).

With the expanding pipeline of vaccine candidates targeting diverse diseases, therapeutic vaccines hold immense potential to address unmet medical needs. Thus, a strong pipeline of candidates for therapeutic vaccines signifies lucrative growth opportunities for the therapeutic vaccines market.

Therapeutic Vaccines Market Report Segmentation Analysis

Key segments that were the foundation of the therapeutic vaccines market analysis are product, technology, and end user.

• Based on product, the therapeutic vaccines market is categorized into cancer vaccines, infectious disease vaccines, and others. The cancer vaccines segment held the largest share of the market in 2024.
• Based on technology, the market is bifurcated into allogenic vaccines and autologous vaccines. The autologous vaccine segment held a larger therapeutic vaccines market share in 2024.
• In terms of end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment dominated the market in 2024.

Therapeutic Vaccines Market Share Analysis by Geography

The geographic scope of the therapeutic vaccines market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America held a significant share of the market in 2024. The regional market growth is driven by rising cancer incidence, increasing investments in research and development, and a surge in product launches. Additionally, strategic initiatives such as the development of new products, regulatory approvals, collaborations, and acquisitions are further propelling the expansion of the therapeutic vaccine market in the region. According to the American Cancer Society, in 2022, more than 1.9 million new cases of cancer were diagnosed in the nation, causing ~0.61 million deaths. In 2024, 2.0 million people in the US were diagnosed with cancer. The rising number of cancer cases ultimately fuels the demand for innovative treatment options. Therapeutic vaccines, designed to stimulate the immune system to target cancer cells, offer promising alternatives to traditional therapies. In 2010, Provenge (sipuleucel-T) became the first therapeutic cancer vaccine to receive approval from the FDA. It is specifically designed for prostate cancer, highlighting the potential for immunotherapy to provide life-extending treatments. This rising number of cases propels research and development investments as well as encourages collaborations among companies and academic institutions.

The Canadian government plays a crucial role through funding initiatives and providing grants to support early-stage cancer research. In September 2024, researchers at the University of British Columbia (UBC) within Canada's Immuno-Engineering and Biomanufacturing Hub (CIEBH) were awarded over US$ 31.4 million in provincial funding for three projects aimed at advancing the development of vaccines and therapeutics in British Columbia for all Canadians. The funding, provided through the BC Knowledge Development Fund (BCKDF), will support the establishment of cutting-edge research infrastructure, including an Advanced Therapeutics Manufacturing Facility (ATMF) on UBC's Vancouver campus. This facility will enable the development and production of clinical-grade treatments that meet Health Canada's rigorous quality standards for clinical trials. These projects align with CIEBH's mission to position BC and Canada as global leaders in next-generation immune-based therapeutics, including mRNA vaccines, antibody treatments, and cell- and gene-based therapies.

Therapeutic Vaccines Market Report Scope

Therapeutic Vaccines Market News and Recent Developments

The therapeutic vaccines market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the therapeutic vaccines market are listed below:

• TheraVectys has announced the enrollment of the first patient in Phase I/IIa clinical trial assessing the oncotherapeutic vaccine Lenti-HPV-07 for the treatment of HPV-induced cancers. Lenti-HPV-07 vaccine is based on the lentiviral vector technology platform developed by the Pasteur-TheraVectys Joint Laboratory, and TheraVectys has pioneered it over the past two decades. (Source: TheraVectys, Press Release, October 2024)
• Serum Institute of India, the world's largest vaccine manufacturer by dose volume, entered into an exclusive global agreement with ImmunityBio, Inc., to supply Bacillus Calmette-Guerin (BCG) to ImmunityBio. The deal includes the production of standard BCG, approved for use outside the US, and a next-generation recombinant BCG (iBCG), currently undergoing testing. The iBCG is intended for use in combination with ImmunityBio's ANKTIVA for both approved and potential future indications, subject to regulatory approval. The two companies will collaborate to expedite the Phase 2 clinical trials of iBCG being conducted in Europe. (Source: Serum Institute of India Pvt. Ltd, Press Release, May 2024)

Therapeutic Vaccines Market Report Coverage and Deliverables

The "Therapeutic Vaccines Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Therapeutic vaccines market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Therapeutic vaccines market trends and market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Therapeutic vaccines market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the therapeutic vaccines market
• Detailed company profiles